 | • レポートコード：GIR-107A12301 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、糸球体腎炎治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。糸球体腎炎治療の種類別市場規模（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002）、用途別市場規模（在宅ケア、クリニック、病院）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・糸球体腎炎治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Achillion Pharmaceuticals Inc、Anthera Pharmaceuticals Inc、Biogen Inc、Bristol-Myers Squibb Company、Cellmid Ltd、ChemoCentryx Inc、Complexa Inc、Dimerix Bioscience Pty Ltd、GlaxoSmithKline Plc、Merck KGaA、Omeros Corp、Pfizer Inc、Pharmalink AB、Ra Pharmaceuticals Inc、Retrophin Inc、Rigel Pharmaceuticals Inc、Takeda、Visterra Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002 ・用途別分析2016年-2026年：在宅ケア、クリニック、病院 ・糸球体腎炎治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・糸球体腎炎治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・糸球体腎炎治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・糸球体腎炎治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・糸球体腎炎治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Glomerulonephritis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Glomerulonephritis Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Glomerulonephritis Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Glomerulonephritis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Market segment by Application, can be divided into
Home Care
Clinic
Hospital
Market segment by players, this report covers
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Takeda
Visterra Inc
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Glomerulonephritis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Glomerulonephritis Treatment, with revenue, gross margin and global market share of Glomerulonephritis Treatment from 2019 to 2021.
Chapter 3, the Glomerulonephritis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Glomerulonephritis Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Glomerulonephritis Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Glomerulonephritis Treatment
1.2 Classification of Glomerulonephritis Treatment by Type
1.2.1 Overview: Global Glomerulonephritis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Glomerulonephritis Treatment Revenue Market Share by Type in 2020
1.2.3 ACH-5228
1.2.4 AMY-101
1.2.5 Atacicept
1.2.6 Avacopan
1.2.7 AVX-002
1.3 Global Glomerulonephritis Treatment Market by Application
1.3.1 Overview: Global Glomerulonephritis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Home Care
1.3.3 Clinic
1.3.4 Hospital
1.4 Global Glomerulonephritis Treatment Market Size & Forecast
1.5 Global Glomerulonephritis Treatment Market Size and Forecast by Region
1.5.1 Global Glomerulonephritis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Glomerulonephritis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Glomerulonephritis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Glomerulonephritis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Glomerulonephritis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Glomerulonephritis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Glomerulonephritis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Glomerulonephritis Treatment Market Drivers
1.6.2 Glomerulonephritis Treatment Market Restraints
1.6.3 Glomerulonephritis Treatment Trends Analysis
2 Company Profiles
2.1 Achillion Pharmaceuticals Inc
2.1.1 Achillion Pharmaceuticals Inc Details
2.1.2 Achillion Pharmaceuticals Inc Major Business
2.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
2.1.4 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Achillion Pharmaceuticals Inc Recent Developments and Future Plans
2.2 Anthera Pharmaceuticals Inc
2.2.1 Anthera Pharmaceuticals Inc Details
2.2.2 Anthera Pharmaceuticals Inc Major Business
2.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
2.2.4 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Anthera Pharmaceuticals Inc Recent Developments and Future Plans
2.3 Biogen Inc
2.3.1 Biogen Inc Details
2.3.2 Biogen Inc Major Business
2.3.3 Biogen Inc Glomerulonephritis Treatment Product and Solutions
2.3.4 Biogen Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Biogen Inc Recent Developments and Future Plans
2.4 Bristol-Myers Squibb Company
2.4.1 Bristol-Myers Squibb Company Details
2.4.2 Bristol-Myers Squibb Company Major Business
2.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Product and Solutions
2.4.4 Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.5 Cellmid Ltd
2.5.1 Cellmid Ltd Details
2.5.2 Cellmid Ltd Major Business
2.5.3 Cellmid Ltd Glomerulonephritis Treatment Product and Solutions
2.5.4 Cellmid Ltd Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Cellmid Ltd Recent Developments and Future Plans
2.6 ChemoCentryx Inc
2.6.1 ChemoCentryx Inc Details
2.6.2 ChemoCentryx Inc Major Business
2.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Product and Solutions
2.6.4 ChemoCentryx Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 ChemoCentryx Inc Recent Developments and Future Plans
2.7 Complexa Inc
2.7.1 Complexa Inc Details
2.7.2 Complexa Inc Major Business
2.7.3 Complexa Inc Glomerulonephritis Treatment Product and Solutions
2.7.4 Complexa Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Complexa Inc Recent Developments and Future Plans
2.8 Dimerix Bioscience Pty Ltd
2.8.1 Dimerix Bioscience Pty Ltd Details
2.8.2 Dimerix Bioscience Pty Ltd Major Business
2.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product and Solutions
2.8.4 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Dimerix Bioscience Pty Ltd Recent Developments and Future Plans
2.9 GlaxoSmithKline Plc
2.9.1 GlaxoSmithKline Plc Details
2.9.2 GlaxoSmithKline Plc Major Business
2.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Product and Solutions
2.9.4 GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 GlaxoSmithKline Plc Recent Developments and Future Plans
2.10 Merck KGaA
2.10.1 Merck KGaA Details
2.10.2 Merck KGaA Major Business
2.10.3 Merck KGaA Glomerulonephritis Treatment Product and Solutions
2.10.4 Merck KGaA Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Merck KGaA Recent Developments and Future Plans
2.11 Omeros Corp
2.11.1 Omeros Corp Details
2.11.2 Omeros Corp Major Business
2.11.3 Omeros Corp Glomerulonephritis Treatment Product and Solutions
2.11.4 Omeros Corp Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Omeros Corp Recent Developments and Future Plans
2.12 Pfizer Inc
2.12.1 Pfizer Inc Details
2.12.2 Pfizer Inc Major Business
2.12.3 Pfizer Inc Glomerulonephritis Treatment Product and Solutions
2.12.4 Pfizer Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Pfizer Inc Recent Developments and Future Plans
2.13 Pharmalink AB
2.13.1 Pharmalink AB Details
2.13.2 Pharmalink AB Major Business
2.13.3 Pharmalink AB Glomerulonephritis Treatment Product and Solutions
2.13.4 Pharmalink AB Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Pharmalink AB Recent Developments and Future Plans
2.14 Ra Pharmaceuticals Inc
2.14.1 Ra Pharmaceuticals Inc Details
2.14.2 Ra Pharmaceuticals Inc Major Business
2.14.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
2.14.4 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Ra Pharmaceuticals Inc Recent Developments and Future Plans
2.15 Retrophin Inc
2.15.1 Retrophin Inc Details
2.15.2 Retrophin Inc Major Business
2.15.3 Retrophin Inc Glomerulonephritis Treatment Product and Solutions
2.15.4 Retrophin Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Retrophin Inc Recent Developments and Future Plans
2.16 Rigel Pharmaceuticals Inc
2.16.1 Rigel Pharmaceuticals Inc Details
2.16.2 Rigel Pharmaceuticals Inc Major Business
2.16.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
2.16.4 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Rigel Pharmaceuticals Inc Recent Developments and Future Plans
2.17 Takeda
2.17.1 Takeda Details
2.17.2 Takeda Major Business
2.17.3 Takeda Glomerulonephritis Treatment Product and Solutions
2.17.4 Takeda Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Takeda Recent Developments and Future Plans
2.18 Visterra Inc
2.18.1 Visterra Inc Details
2.18.2 Visterra Inc Major Business
2.18.3 Visterra Inc Glomerulonephritis Treatment Product and Solutions
2.18.4 Visterra Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Visterra Inc Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Glomerulonephritis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Glomerulonephritis Treatment Players Market Share
3.2.2 Top 10 Glomerulonephritis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Glomerulonephritis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Glomerulonephritis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Glomerulonephritis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Glomerulonephritis Treatment Revenue Market Share by Application (2016-2021)
5.2 Glomerulonephritis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Glomerulonephritis Treatment Revenue by Type (2016-2026)
6.2 North America Glomerulonephritis Treatment Revenue by Application (2016-2026)
6.3 North America Glomerulonephritis Treatment Market Size by Country
6.3.1 North America Glomerulonephritis Treatment Revenue by Country (2016-2026)
6.3.2 United States Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Glomerulonephritis Treatment Revenue by Type (2016-2026)
7.2 Europe Glomerulonephritis Treatment Revenue by Application (2016-2026)
7.3 Europe Glomerulonephritis Treatment Market Size by Country
7.3.1 Europe Glomerulonephritis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Glomerulonephritis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Glomerulonephritis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Glomerulonephritis Treatment Market Size by Region
8.3.1 Asia-Pacific Glomerulonephritis Treatment Revenue by Region (2016-2026)
8.3.2 China Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Glomerulonephritis Treatment Revenue by Type (2016-2026)
9.2 South America Glomerulonephritis Treatment Revenue by Application (2016-2026)
9.3 South America Glomerulonephritis Treatment Market Size by Country
9.3.1 South America Glomerulonephritis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Glomerulonephritis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Glomerulonephritis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Glomerulonephritis Treatment Market Size by Country
10.3.1 Middle East & Africa Glomerulonephritis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Glomerulonephritis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Glomerulonephritis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Glomerulonephritis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Glomerulonephritis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Glomerulonephritis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Glomerulonephritis Treatment Revenue Market Share by Region (2021-2026)
Table 6. Achillion Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 7. Achillion Pharmaceuticals Inc Major Business
Table 8. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 9. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Anthera Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 11. Anthera Pharmaceuticals Inc Major Business
Table 12. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 13. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Biogen Inc Corporate Information, Head Office, and Major Competitors
Table 15. Biogen Inc Major Business
Table 16. Biogen Inc Glomerulonephritis Treatment Product and Solutions
Table 17. Biogen Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Company Major Business
Table 20. Bristol-Myers Squibb Company Glomerulonephritis Treatment Product and Solutions
Table 21. Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Cellmid Ltd Corporate Information, Head Office, and Major Competitors
Table 23. Cellmid Ltd Major Business
Table 24. Cellmid Ltd Glomerulonephritis Treatment Product and Solutions
Table 25. Cellmid Ltd Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. ChemoCentryx Inc Corporate Information, Head Office, and Major Competitors
Table 27. ChemoCentryx Inc Major Business
Table 28. ChemoCentryx Inc Glomerulonephritis Treatment Product and Solutions
Table 29. ChemoCentryx Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Complexa Inc Corporate Information, Head Office, and Major Competitors
Table 31. Complexa Inc Major Business
Table 32. Complexa Inc Glomerulonephritis Treatment Product and Solutions
Table 33. Complexa Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Dimerix Bioscience Pty Ltd Corporate Information, Head Office, and Major Competitors
Table 35. Dimerix Bioscience Pty Ltd Major Business
Table 36. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product and Solutions
Table 37. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. GlaxoSmithKline Plc Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline Plc Major Business
Table 40. GlaxoSmithKline Plc Glomerulonephritis Treatment Product and Solutions
Table 41. GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Merck KGaA Corporate Information, Head Office, and Major Competitors
Table 43. Merck KGaA Major Business
Table 44. Merck KGaA Glomerulonephritis Treatment Product and Solutions
Table 45. Merck KGaA Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Omeros Corp Corporate Information, Head Office, and Major Competitors
Table 47. Omeros Corp Major Business
Table 48. Omeros Corp Glomerulonephritis Treatment Product and Solutions
Table 49. Omeros Corp Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 51. Pfizer Inc Major Business
Table 52. Pfizer Inc Glomerulonephritis Treatment Product and Solutions
Table 53. Pfizer Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Pharmalink AB Corporate Information, Head Office, and Major Competitors
Table 55. Pharmalink AB Major Business
Table 56. Pharmalink AB Glomerulonephritis Treatment Product and Solutions
Table 57. Pharmalink AB Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Ra Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 59. Ra Pharmaceuticals Inc Major Business
Table 60. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 61. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Retrophin Inc Corporate Information, Head Office, and Major Competitors
Table 63. Retrophin Inc Major Business
Table 64. Retrophin Inc Glomerulonephritis Treatment Product and Solutions
Table 65. Retrophin Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Rigel Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 67. Rigel Pharmaceuticals Inc Major Business
Table 68. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 69. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Takeda Corporate Information, Head Office, and Major Competitors
Table 71. Takeda Major Business
Table 72. Takeda Glomerulonephritis Treatment Product and Solutions
Table 73. Takeda Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Visterra Inc Corporate Information, Head Office, and Major Competitors
Table 75. Visterra Inc Major Business
Table 76. Visterra Inc Glomerulonephritis Treatment Product and Solutions
Table 77. Visterra Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Global Glomerulonephritis Treatment Revenue (USD Million) by Players (2019-2021)
Table 79. Global Glomerulonephritis Treatment Revenue Share by Players (2019-2021)
Table 80. Breakdown of Glomerulonephritis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 81. Glomerulonephritis Treatment Players Head Office, Products and Services Provided
Table 82. Glomerulonephritis Treatment Mergers & Acquisitions in the Past Five Years
Table 83. Glomerulonephritis Treatment New Entrants and Expansion Plans
Table 84. Global Glomerulonephritis Treatment Revenue (USD Million) by Type (2016-2021)
Table 85. Global Glomerulonephritis Treatment Revenue Share by Type (2016-2021)
Table 86. Global Glomerulonephritis Treatment Revenue Forecast by Type (2021-2026)
Table 87. Global Glomerulonephritis Treatment Revenue by Application (2016-2021)
Table 88. Global Glomerulonephritis Treatment Revenue Forecast by Application (2021-2026)
Table 89. North America Glomerulonephritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 90. North America Glomerulonephritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 91. North America Glomerulonephritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 92. North America Glomerulonephritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 93. North America Glomerulonephritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 94. North America Glomerulonephritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 95. Europe Glomerulonephritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 96. Europe Glomerulonephritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 97. Europe Glomerulonephritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 98. Europe Glomerulonephritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 99. Europe Glomerulonephritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 100. Europe Glomerulonephritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 101. Asia-Pacific Glomerulonephritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 102. Asia-Pacific Glomerulonephritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 103. Asia-Pacific Glomerulonephritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 104. Asia-Pacific Glomerulonephritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 105. Asia-Pacific Glomerulonephritis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 106. Asia-Pacific Glomerulonephritis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 107. South America Glomerulonephritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 108. South America Glomerulonephritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 109. South America Glomerulonephritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 110. South America Glomerulonephritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 111. South America Glomerulonephritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 112. South America Glomerulonephritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 113. Middle East & Africa Glomerulonephritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 114. Middle East & Africa Glomerulonephritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 115. Middle East & Africa Glomerulonephritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 116. Middle East & Africa Glomerulonephritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 117. Middle East & Africa Glomerulonephritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 118. Middle East & Africa Glomerulonephritis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Glomerulonephritis Treatment Picture
Figure 2. Global Glomerulonephritis Treatment Revenue Market Share by Type in 2020
Figure 3. ACH-5228
Figure 4. AMY-101
Figure 5. Atacicept
Figure 6. Avacopan
Figure 7. AVX-002
Figure 8. Glomerulonephritis Treatment Revenue Market Share by Application in 2020
Figure 9. Home Care Picture
Figure 10. Clinic Picture
Figure 11. Hospital Picture
Figure 12. Global Glomerulonephritis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Glomerulonephritis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Glomerulonephritis Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Glomerulonephritis Treatment Revenue Market Share by Region in 2020
Figure 16. North America Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Glomerulonephritis Treatment Market Drivers
Figure 22. Glomerulonephritis Treatment Market Restraints
Figure 23. Glomerulonephritis Treatment Market Trends
Figure 24. Achillion Pharmaceuticals Inc Recent Developments and Future Plans
Figure 25. Anthera Pharmaceuticals Inc Recent Developments and Future Plans
Figure 26. Biogen Inc Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 28. Cellmid Ltd Recent Developments and Future Plans
Figure 29. ChemoCentryx Inc Recent Developments and Future Plans
Figure 30. Complexa Inc Recent Developments and Future Plans
Figure 31. Dimerix Bioscience Pty Ltd Recent Developments and Future Plans
Figure 32. GlaxoSmithKline Plc Recent Developments and Future Plans
Figure 33. Merck KGaA Recent Developments and Future Plans
Figure 34. Omeros Corp Recent Developments and Future Plans
Figure 35. Pfizer Inc Recent Developments and Future Plans
Figure 36. Pharmalink AB Recent Developments and Future Plans
Figure 37. Ra Pharmaceuticals Inc Recent Developments and Future Plans
Figure 38. Retrophin Inc Recent Developments and Future Plans
Figure 39. Rigel Pharmaceuticals Inc Recent Developments and Future Plans
Figure 40. Takeda Recent Developments and Future Plans
Figure 41. Visterra Inc Recent Developments and Future Plans
Figure 42. Global Glomerulonephritis Treatment Revenue Share by Players in 2020
Figure 43. Glomerulonephritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 44. Global Top 3 Players Glomerulonephritis Treatment Revenue Market Share in 2020
Figure 45. Global Top 10 Players Glomerulonephritis Treatment Revenue Market Share in 2020
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 47. Global Glomerulonephritis Treatment Revenue Share by Type in 2020
Figure 48. Global Glomerulonephritis Treatment Market Share Forecast by Type (2021-2026)
Figure 49. Global Glomerulonephritis Treatment Revenue Share by Application in 2020
Figure 50. Global Glomerulonephritis Treatment Market Share Forecast by Application (2021-2026)
Figure 51. North America Glomerulonephritis Treatment Sales Market Share by Type (2016-2026)
Figure 52. North America Glomerulonephritis Treatment Sales Market Share by Application (2016-2026)
Figure 53. North America Glomerulonephritis Treatment Revenue Market Share by Country (2016-2026)
Figure 54. United States Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Canada Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Mexico Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Europe Glomerulonephritis Treatment Sales Market Share by Type (2016-2026)
Figure 58. Europe Glomerulonephritis Treatment Sales Market Share by Application (2016-2026)
Figure 59. Europe Glomerulonephritis Treatment Revenue Market Share by Country (2016-2026)
Figure 60. Germany Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. France Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. United Kingdom Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Russia Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Italy Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Asia-Pacific Glomerulonephritis Treatment Sales Market Share by Type (2016-2026)
Figure 66. Asia-Pacific Glomerulonephritis Treatment Sales Market Share by Application (2016-2026)
Figure 67. Asia-Pacific Glomerulonephritis Treatment Revenue Market Share by Region (2016-2026)
Figure 68. China Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Japan Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South Korea Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. India Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Southeast Asia Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Australia Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. South America Glomerulonephritis Treatment Sales Market Share by Type (2016-2026)
Figure 75. South America Glomerulonephritis Treatment Sales Market Share by Application (2016-2026)
Figure 76. South America Glomerulonephritis Treatment Revenue Market Share by Country (2016-2026)
Figure 77. Brazil Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Argentina Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Middle East and Africa Glomerulonephritis Treatment Sales Market Share by Type (2016-2026)
Figure 80. Middle East and Africa Glomerulonephritis Treatment Sales Market Share by Application (2016-2026)
Figure 81. Middle East and Africa Glomerulonephritis Treatment Revenue Market Share by Country (2016-2026)
Figure 82. Turkey Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Saudi Arabia Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. UAE Glomerulonephritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source
世界の軟骨無形成症治療市場 2021：企業別、地域別、種類・用途別 The Achondroplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…- 世界の髄膜炎菌感染症治療市場 2021：企業別、地域別、種類・用途別 The Meningococcal Infections Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 世界の総胆管結石症治療市場 2021：企業別、地域別、種類・用途別 The Choledocholithiasis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の黄熱病治療市場 2021：企業別、地域別、種類・用途別 The Yellow Fever Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulati…
- 世界の家族性大腸腺腫症治療市場 2021：企業別、地域別、種類・用途別 The Familial Adenomatous Polyposis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…